Aurobindo Pharma's Aciclovir Supplement Application Receives Standard Review Status
Aurobindo Pharma USA has submitted a supplement application for Aciclovir (ANDA075211) which is currently under standard review by the FDA.
Asset / Drug
Drug and asset intelligence for Aciclovir with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.